(Q36044190)

11 August 2017

1 reference

title

The role of the gut microbiota in NAFLD. (English)

1 reference

11 August 2017

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27273168%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

Christopher Leung

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27273168%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Leni Rivera

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27273168%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Peter W Angus

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27273168%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

language of work or name

English

0 references

publication date

8 June 2016

1 reference

Nature Reviews Gastroenterology & Hepatology

11 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27273168%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27273168%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27273168%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

412-425

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27273168%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrgastro.2016.85

8 June 2020

exact match

0 references

cites work

The global NAFLD epidemic

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

From fatty liver to fibrosis: a tale of "second hit".

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Advanced glycation end products augment experimental hepatic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

The interpersonal and intrapersonal diversity of human-associated microbiota in key body sites

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Structure, function and diversity of the healthy human microbiome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Functional interactions between the gut microbiota and host metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Intestinal microbiota during infancy and its implications for obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Altering the Intestinal Microbiota during a Critical Developmental Window Has Lasting Metabolic Consequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

The isolation of antibiotic-resistant salmonella from retail ground meats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

An obesity-associated gut microbiome with increased capacity for energy harvest

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Microbial ecology: human gut microbes associated with obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Antibiotics in early life alter the murine colonic microbiome and adiposity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

A core gut microbiome in obese and lean twins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Electron transfer in syntrophic communities of anaerobic bacteria and archaea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Carotid stenosis: from diagnosis to management, where do we stand?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Trials of obeticholic acid for non-alcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Trials of obeticholic acid for non-alcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Intestinal farnesoid X receptor puts a fresh coat of wax on fatty liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

The role of pH in determining the species composition of the human colonic microbiota

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Obesity, fatty liver disease and intestinal microbiota

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Short-chain fatty acids suppress cholesterol synthesis in rat liver and intestine.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Short-Chain Fatty Acids Protect Against High-Fat Diet-Induced Obesity via a PPARγ-Dependent Switch From Lipogenesis to Fat Oxidation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

31 March 2020

You are what you eat.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Intestinal microbiota in patients with nonalcoholic fatty liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Implication of gut microbiota in nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Fecal Microbiome and Volatile Organic Compound Metabolome in Obese Humans With Nonalcoholic Fatty Liver Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Immunology. Feed your Tregs more fiber.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

The role of sodium-coupled glucose co-transporter 3 in the satiety effect of portal glucose sensing.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

The gut microbiota as an environmental factor that regulates fat storage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Short-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor γ

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Human, donkey and cow milk differently affects energy efficiency and inflammatory state by modulating mitochondrial function and gut microbiota

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Metabolic endotoxemia initiates obesity and insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Enhanced AMPK phosphorylation contributes to the beneficial effects of Lactobacillus rhamnosus GG supernatant on chronic-alcohol-induced fatty liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

A concise review of non-alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Toll-like receptors as targets in chronic liver diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

A deer in the headlights: BAMBI meets liver fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Effects of bacterial products on enterocyte-macrophage interactions in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

The NF-kappa B and I kappa B proteins: new discoveries and insights

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

NLRP3 inflammasome activation is required for fibrosis development in NAFLD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Is predisposition to NAFLD and obesity communicable?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Methods to determine intestinal permeability and bacterial translocation during liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: a randomized controlled crossover trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Evaluation of gut bacterial populations using an electronic e-nose and field asymmetric ion mobility spectrometry: further insights into 'fermentonomics'.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Liver-spleen axis: intersection between immunity, infections and metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Colloid scintigraphy in non-alcoholic steatohepatitis: a conventional diagnostic method for an emerging disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Damage to enteric neurons occurs in mice that develop fatty liver disease but not diabetes in response to a high-fat diet.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

The formation of ethanol in Escherichia coli

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Role of alcohol metabolism in non-alcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Crosstalk between Gut Microbiota and Dietary Lipids Aggravates WAT Inflammation through TLR Signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

High-fat diet reduces the formation of butyrate, but increases succinate, inflammation, liver fat and cholesterol in rats, while dietary fibre counteracts these effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Temporal pattern of de novo lipogenesis in the postprandial state in healthy men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Overstated Associations Between Fructose and Nonalcoholic Fatty Liver Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Sugar sweetened beverages and fatty liver disease: Rising concern and call to action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Advanced glycation end products as environmental risk factors for the development of type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Evidence of involvement of the receptor for advanced glycation end-products (RAGE) in the adhesion of Helicobacter pylori to gastric epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

The functional -374T/A polymorphism of the receptor for advanced glycation end products may modulate Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Role of the advanced glycation end products receptor in Crohn's disease inflammation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Dietary glycotoxins exacerbate progression of experimental fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Artificial sweeteners induce glucose intolerance by altering the gut microbiota

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Gut microbial adaptation to dietary consumption of fructose, artificial sweeteners and sugar alcohols: implications for host-microbe interactions contributing to obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Artificial sweeteners produce the counterintuitive effect of inducing metabolic derangements

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Paediatric non-alcoholic fatty liver disease: an overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Formaldehyde derived from dietary aspartame binds to tissue components in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Diet macronutrients composition in nonalcoholic Fatty liver disease: a review on the related documents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Fermented green tea extract alleviates obesity and related complications and alters gut microbiota composition in diet-induced obese mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, stimulates hepatic autophagy and lipid clearance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Decaffeinated green tea extract rich in epigallocatechin-3-gallate prevents fatty liver disease by increased activities of mitochondrial respiratory chain complexes in diet-induced obesity mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Coffee but not green tea consumption is associated with prevalence and severity of hepatic steatosis: the impact on leptin level

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Letter: gut microbiota modulation contributes to coffee's benefits for non-alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Influence of coffee (Coffea arabica) and galacto-oligosaccharide consumption on intestinal microbiota and the host responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Chronic coffee consumption in the diet-induced obese rat: impact on gut microbiota and serum metabolomics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Effects of poor and short sleep on glucose metabolism and obesity risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Insufficient Sleep Undermines Dietary Efforts to Reduce Adiposity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Circadian disorganization alters intestinal microbiota

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Disruption of the Circadian Clock in Mice Increases Intestinal Permeability and Promotes Alcohol-Induced Hepatic Pathology and Inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Origin and evolution of circadian clock genes in prokaryotes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Intermittent hypoxia alters gut microbiota diversity in a mouse model of sleep apnoea.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Non-alcoholic fatty liver disease and increased risk of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Meta-analysis of workplace physical activity interventions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Exercise prevents weight gain and alters the gut microbiota in a mouse model of high fat diet-induced obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Voluntary running exercise alters microbiota composition and increases n-butyrate concentration in the rat cecum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Exercise and associated dietary extremes impact on gut microbial diversity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Green tea extract improves running endurance in mice by stimulating lipid utilization during exercise

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Pharmacology, physiology, and mechanisms of incretin hormone action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Probiotics in Pediatric Liver Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Prebiotics, probiotics, synbiotics, and the immune system: experimental data and clinical evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Roles for chemokines in liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Pharmacological agents for NASH.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

The human microbiome: at the interface of health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Diversity of the human intestinal microbial flora

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

The intestinal microbiota and chronic disorders of the gut.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Viruses in the faecal microbiota of monozygotic twins and their mothers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Kingdom-agnostic metagenomics and the importance of complete characterization of enteric microbial communities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

The human milk microbiota: origin and potential roles in health and disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Distinct gut microbiota in southeastern African and northern European infants.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

A protective effect of breastfeeding on the progression of non-alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Maternal obesity during pregnancy and lactation programs the development of offspring non-alcoholic fatty liver disease in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.85

Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study

31 March 2020

1 reference

12 December 2020

Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic "mal-programming".

1 reference

12 December 2020

SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease

1 reference

12 December 2020

Rapid and simultaneous quantification of rhamnose, mannitol, and lactulose in urine by HPLC for estimating intestinal permeability in pediatric practice

1 reference

12 December 2020

Targeting Dysbiosis for the Treatment of Liver Disease

1 reference

12 December 2020

Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease

1 reference

12 December 2020

Experimental evidence of obstructive sleep apnea syndrome as a second hit accomplice in nonalcoholic steatohepatitis pathogenesis.

1 reference

12 December 2020

Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients?

1 reference

12 December 2020

Adaptation to overeating in lean and overweight men and women

1 reference

12 December 2020

FXR agonists as therapeutic agents for non-alcoholic fatty liver disease

1 reference

12 December 2020

Dietary intake, energy metabolism, and excretory losses of adult male germfree Wistar rats

1 reference

12 December 2020

The Effect of Green Tea Extract Supplementation on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease

1 reference

12 December 2020

Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRGASTRO.2016.85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27273168%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1 reference